Given the clinical approval of the Hedgehog signaling inhibitor Glasdegib for AML treatment, we explored whether the expression of the downstream Hedgehog effector Gli1 is dependent on FASN activity to identify potential additional treatment strategies. This evidence concerns the gene FASN and acute myeloid leukemia.